News & Resources

2014 Press Releases

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Media Contact:
David Walsey
BrewLife
Phone: (858) 617-0772
Email:dwalsey@brewlife.com

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/19/14Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European UnionPrinter Friendly Version
11/26/14Orexigen Therapeutics to Present at the Piper Jaffray Healthcare ConferencePrinter Friendly Version
11/21/14Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)Printer Friendly Version
11/10/14Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014Printer Friendly Version
11/06/14Orexigen Therapeutics to Present at the Credit Suisse Healthcare ConferencePrinter Friendly Version
11/04/14Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and WebcastPrinter Friendly Version
10/31/14Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in BostonPrinter Friendly Version
10/20/14Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese AdultsPrinter Friendly Version
10/15/14Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial LaunchPrinter Friendly Version
09/16/14Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare ConferencePrinter Friendly Version
09/11/14Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management Printer Friendly Version
09/10/14Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014Printer Friendly Version
09/02/14Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. PatentPrinter Friendly Version
08/07/14Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014Printer Friendly Version
07/31/14Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and WebcastPrinter Friendly Version
07/30/14Orexigen Receives CHMP Day 180 List of Outstanding IssuesPrinter Friendly Version
06/13/14Orexigen Therapeutics to Present at the Wells Fargo Securities 2014 Healthcare ConferencePrinter Friendly Version
06/11/14Orexigen Receives Three Month Extension of FDA NB32 ReviewPrinter Friendly Version
06/02/14Orexigen Announces June 11, 2014 PDUFA Action Date for NB32Printer Friendly Version
05/09/14Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care ConferencePrinter Friendly Version
05/08/14Orexigen Therapeutics Reports Corporate and Financial Results for the First Quarter Ended March 31, 2014Printer Friendly Version
05/01/14Orexigen Therapeutics to Host First Quarter 2014 Financial Results Conference Call and WebcastPrinter Friendly Version
03/12/14Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013Printer Friendly Version
03/03/14Orexigen Therapeutics to Host Full Year and Fourth Quarter 2013 Financial Results Conference Call and WebcastPrinter Friendly Version
02/27/14Orexigen Therapeutics to Present at the 34th Annual Cowen and Co. Health Care ConferencePrinter Friendly Version
02/25/14Orexigen Provides Update on Its NB32 European Marketing Authorization ApplicationPrinter Friendly Version
02/06/14Orexigen Therapeutics to Present at Upcoming Investor ConferencesPrinter Friendly Version
01/07/14Orexigen Announces June 10, 2014 PDUFA Action Date for ContravePrinter Friendly Version
01/06/14Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare ConferencePrinter Friendly Version